These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18770489)

  • 1. Measuring the effect of a study meal on portal concentrations of glucagon-like peptide 1 (GLP-1) in non diabetic and diabetic patients with liver cirrhosis: transjugular intrahepatic portosystemic stent shunt (TIPSS) as a new method for metabolic measurements.
    Raddatz D; Nolte W; Rossbach C; Leonhardt U; Buchwald A; Scholz KH; Ramadori G
    Exp Clin Endocrinol Diabetes; 2008 Aug; 116(8):461-7. PubMed ID: 18770489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients.
    Su AP; Cao SS; Le Tian B; Da Zhang Z; Hu WM; Zhang Y; Wang ZL; Babu SR; Hu T
    Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):53-9. PubMed ID: 22099870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS).
    Raddatz D; Rossbach C; Buchwald A; Scholz KH; Ramadori G; Nolte W
    Exp Clin Endocrinol Diabetes; 2005 May; 113(5):268-74. PubMed ID: 15926112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical results and hemodynamic changes of portal venous system in transjugular intrahepatic portosystemic stent shunt].
    Wu X; Cao J; Wu X
    Zhonghua Wai Ke Za Zhi; 1996 May; 34(5):303-6. PubMed ID: 9387710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
    Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and splanchnic endothelin-1 plasma levels in liver cirrhosis before and after transjugular intrahepatic portosystemic shunt (TIPS).
    Nolte W; Ehrenreich H; Wiltfang J; Pahl K; Unterberg K; Kamrowski-Kruck H; Schindler CG; Figulla HR; Buchwald AB; Hartmann H; Ramadori G
    Liver; 2000 Feb; 20(1):60-5. PubMed ID: 10726962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents.
    Ockenga J; Kroencke TJ; Schuetz T; Plauth M; Kasim E; Petersein J; Schmidt HH; Lochs H
    Scand J Gastroenterol; 2004 Oct; 39(10):994-9. PubMed ID: 15513340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct measurement of post-prandial portal haemodynamics in cirrhotic patients with a transjugular intrahepatic portosystemic stent-shunt.
    Stanley AJ; Forrest EH; Redhead DN; Bouchier IA; Hayes PC
    Eur J Gastroenterol Hepatol; 1998 May; 10(5):393-7. PubMed ID: 9619385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of transjugular intrahepatic portosystemic shunt for portal hypertension in autosomal recessive polycystic kidney disease.
    Verbeeck S; Mekhali D; Cassiman D; Maleux G; Witters P
    Dig Liver Dis; 2018 Jul; 50(7):707-712. PubMed ID: 29622386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial.
    Sauer P; Theilmann L; Herrmann S; Bruckner T; Roeren T; Richter G; Stremmel W; Stiehl A
    Hepatology; 1996 Dec; 24(6):1433-6. PubMed ID: 8938176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sleep disorders and portal-systemic encephalopathy following transjugular intrahepatic portosystemic stent shunt in patients with liver cirrhosis. Relation to plasma tryptophan.
    Wiltfang J; Nolte W; von Heppe J; Bahn E; Pilz J; Hajak G; Rüther E; Ramadori G
    Adv Exp Med Biol; 1999; 467():169-76. PubMed ID: 10721053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipopolysaccharide-Induced Neutrophil Dysfunction Following Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Insertion is Associated with Organ Failure and Mortality.
    Macnaughtan J; Mookerjee RP; van der Merwe S; Jalan R
    Sci Rep; 2017 Jan; 7():40157. PubMed ID: 28051160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of transjugular portosystemic shunt on insulin resistance].
    Stefánková J; Safka V; Fejfar T; Hůlek P; Dresslerová I; Krajina A
    Vnitr Lek; 2002 Nov; 48(11):1017-24. PubMed ID: 12577452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Portal vein thrombosis after occlusion of a transjugular intrahepatic portosystemic stent-shunt (TIPSS). Shunt dilatation with subsequent local and systemic thrombolysis].
    Gabler R; Barnert J; Bohndorf K; Eberl T; Wienbeck M
    Dtsch Med Wochenschr; 1997 Feb; 122(7):188-92. PubMed ID: 9072489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of surgical shunts and transjugular intrahepatic portasystemic stent shunts for complicated portal hypertension.
    Hosokawa I; Adam R; Allard MA; Pittau G; Vibert E; Cherqui D; Sa Cunha A; Bismuth H; Miyazaki M; Castaing D
    Br J Surg; 2017 Mar; 104(4):443-451. PubMed ID: 28079252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS).
    Jalan R; Redhead DN; Thomas HW; Henderson N; O'Rourke K; Dillon JF; Williams BC; Hayes PC
    Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1111-6. PubMed ID: 8944375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transjugular intrahepatic portosystemic stent-shunt: technical factors and new developments.
    Tripathi D; Redhead D
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1127-33. PubMed ID: 17033430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).
    Benten D; Schulze zur Wiesch J; Sydow K; Koops A; Buggisch P; Böger RH; Gaydos CA; Won H; Franco V; Lohse AW; Ray SC; Balagopal A
    BMC Gastroenterol; 2011 Oct; 11():107. PubMed ID: 21978390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.